WHAT IS CLAIMED IS:

1. ~~A method of treating cancer in a subject, comprising administering to the subject:~~ Use of:


~~(i)~~ (i) an inhibitor of A2A/A2B;

~~(ii)~~ (ii) an inhibitor of PD-1/PD-L1; and

~~(iii)~~ (iii) an inhibitor of human CD73~~.~~;

in the manufacture of a medicament for the treatment of cancer.

2. The ~~method~~use of claim 1, wherein the inhibitor of A2A/A2B is a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Cy^1 is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

Cy^2 is 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl of Cy^2 are each optionally substituted with 1, 2, or 3 groups each independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, NH_2, $NH(C_{1-3}$ alkyl) and $N(C_{1-3}$ alkyl$)_2$;

R^2 is selected from phenyl-C_{1-3} alkyl-, C_{3-7} cycloalkyl-C_{1-3} alkyl-, (5-7 membered heteroaryl)-C_{1-3} alkyl-, (4-7 membered heterocycloalkyl)-C_{1-3} alkyl-, and OR^{a2}, wherein the phenyl-C_{1-3} alkyl-, C_{3-7} cycloalkyl-C_{1-3} alkyl-, (5-7 membered heteroaryl)-C_{1-3} alkyl-, and (4-7 membered heterocycloalkyl)-C_{1-3} alkyl- of R^2 are each optionally substituted with 1, 2, or 3 independently selected R^C substituents;

R^{a2} is (5-7 membered heteroaryl)-C_{1-3} alkyl- optionally substituted with 1 or 2 independently selected R^C substituents;

each R^C is independently selected from halo, C_{1-6} alkyl, C_6 aryl, 5-7 membered heteroaryl, (4-7 membered heterocycloalkyl)-C_{1-3} alkyl-, OR^{a4}, and $NR^{c4}R^{d4}$; and

each R^{a4}, R^{c4}, and R^{d4} are independently selected from H and C_{1-6} alkyl.

3. The ~~method~~use of claim 1 or 2, wherein the inhibitor of A2A/A2B is selected from:

3-(5-amino-2-(pyridin-2-ylmethyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(5-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;


3-(5-amino-2-((5-(pyridin-2-yl)-2H-tetrazol-2-yl)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(5-amino-2-((3-methylpyridin-2-yl)methoxy)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile; and

3-(2-((5-(1H-pyrazol-1-yl)-2H-tetrazol-2-yl)methyl)-5-amino-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

or a pharmaceutically acceptable salt of any of the aforementioned.

4. The ~~method~~use of claim 1, wherein the inhibitor of A2A/A2B is a compound of Formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

R^2 is selected from H and CN;

Cy^1 is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

L is C_{1-3} alkylene, wherein said alkylene is optionally substituted with 1, 2, or 3 independently selected R^{8D} substituents;

Cy^4 is selected from phenyl, cyclohexyl, pyridyl, pyrrolidinonyl, and imidazolyl, wherein the phenyl, cyclohexyl, pyridyl, pyrrolidinonyl, and imidazolyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{8D} and R^8;

each R^8 is independently selected from halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, (5-6 membered heteroaryl)-C_{1-3} alkyl, and (4-7 membered heterocycloalkyl)-C_{1-3} alkyl, wherein the C_{1-6} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, (5-6 membered heteroaryl)-C_{1-3} alkyl, and (4-7 membered heterocycloalkyl)-C_{1-3} alkyl of R^8 are each optionally substituted with 1, 2, or 3 independently selected R^{8A} substituents;

each R^{8A} is independently selected from halo, C_{1-6} alkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, OR^{a81}, and $NR^{c81}R^{d81}$, wherein the C_{1-6} alkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^{8A} are each optionally substituted with 1, 2, or 3 independently selected R^{8B} substituents;

each R^{a81}, R^{c81}, and R^{d81} is independently selected from H, C_{1-6} alkyl, and 4-7 membered heterocycloalkyl, wherein the C_{1-6} alkyl and 4-7 membered heterocycloalkyl of R^{a81}, R^{c81}, and R^{d81} are each optionally substituted with 1, 2, or 3 independently selected R^{8B} substituents;

each R^{8B} is independently selected from halo and C_{1-3} alkyl; and

each R^{8D} is independently selected from OH, CN, halo, C_{1-6} alkyl, and C_{1-6} haloalkyl.

5. The ~~method~~use of claim 1 or 4, wherein the inhibitor of A2A/A2B is selected from:

3-(5-amino-2-(hydroxy(phenyl)methyl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;


3-(5-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-2-fluorobenzonitrile;

5-amino-7-(3-cyano-2-fluorophenyl)-2-((2,6-difluorophenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-c]pyrimidine-8-carbonitrile; and

3-(5-amino-2-((2-fluoro-6-(((1-methyl-2-oxopyrrolidin-3-yl)amino)methyl)phenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-2-fluorobenzonitrile;

or a pharmaceutically acceptable salt of any of the aforementioned.

6. The ~~method~~use of claim 1, wherein the inhibitor of A2A/A2B is a compound of Formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

Cy^1 is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

R^2 is selected from 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of R^2 are each optionally substituted with 1, 2, or 3 independently selected R^{2A} substituents;

each R^{2A} is independently selected from D, halo, C_{1-6} alkyl, and C_{1-6} haloalkyl;

R^4 is selected from phenyl-C_{1-3} alkyl-, C_{3-7} cycloalkyl-C_{1-3} alkyl-, (5-6 membered heteroaryl)-C_{1-3} alkyl-, and (4-7 membered heterocycloalkyl)-C_{1-3} alkyl wherein the phenyl-C_{1-3} alkyl-, C_{3-7} cycloalkyl-C_{1-3} alkyl-, (5-6 membered heteroaryl)-C_{1-3} alkyl-, and (4-7 membered heterocycloalkyl)-C_{1-3} alkyl- of R^4 are each optionally substituted with 1, 2, or 3 independently selected R^{4A} substituents;

each R^{4A} is independently selected from halo, C_{1-6} alkyl, C_{1-6} haloalkyl, CN, OR^{a41}, and $NR^{c41}R^{d41}$; and

each R^{a41}, R^{c41}, and R^{d41} is independently selected from H and C_{1-6} alkyl.

7. The ~~method~~use of claim 1 or 6, wherein the inhibitor of A2A/A2B is selected from:

3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile;


3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile;

3-(8-amino-2-(amino(2,6-difluorophenyl)methyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; and

3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(2,6-dimethylpyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile;

or a pharmaceutically acceptable salt of any of the aforementioned.

8. The ~~method~~use of claim 1, wherein the inhibitor of A2A/A2B is a compound of Formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein:

Cy^1 is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

Cy^2 is selected from 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of Cy^2 are each optionally substituted with 1, 2, or 3 independently selected R^6 substituents;

each R^6 is independently selected from halo, C_{1-6} alkyl, and C_{1-6} haloalkyl;

R^2 is phenyl-C_{1-3} alkyl- or (5-6 membered heteroaryl)-C_{1-3} alkyl-, wherein the phenyl-C_{1-3} alkyl- and (5-6 membered heteroaryl)-C_{1-3} alkyl- of R^2 are each optionally substituted with 1, 2, or 3 independently selected R^{2A} substituents; and

each R^{2A} is independently selected from halo, C_{1-6} alkyl, and C_{1-6} haloalkyl.

or a pharmaceutically acceptable salt thereof.

9. The ~~method~~use of claim 1 or 8, wherein the inhibitor of A2A/A2B is selected from:

3-(4-amino-2-(pyridin-2-ylmethyl)-7-(pyrimidin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile;

3-(4-amino-2-((3-fluoropyridin-2-yl)methyl)-7-(pyrimidin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile;

3-(4-amino-2-((3-fluoropyridin-2-yl)methyl)-7-(pyridin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile; and

3-(4-amino-7-(1-methyl-1H-pyrazol-5-yl)-2-(pyridin-2-ylmethyl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)-2-fluorobenzonitrile;

or a pharmaceutically acceptable salt of any of the aforementioned.

10. The ~~method~~use of claim 1, wherein the inhibitor of A2A/A2B is 3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.

11. The ~~method~~use of claim 1, wherein the inhibitor of A2A/A2B is 3-(5-amino-2-((5-(pyridin-2-yl)-2H-tetrazol-2-yl)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.

12. The ~~method~~use of any one of claims 1 to 11, wherein the inhibitor of PD-1/PD-L1 is (*R*)-1-((7-cyano-2-(3'-(3-(((*R*)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

13. The ~~method~~use of any one of claims 1 to 11, wherein the inhibitor of PD-1/PD-L1 is pembrolizumab.

14. The ~~method~~use of any one of claims 1 to 11, wherein the inhibitor of PD-1/PD-L1 is atezolizumab.

15. The ~~method~~use of any one of claims 1 to 11, wherein the inhibitor of PD-1/PD-L1 is an antibody or antigen-binding fragment thereof that binds to human PD-1, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy (VH)

domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);

the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and

the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);

the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and

the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11).

16. The ~~method~~use of claim 15, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:4 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:5.

17. The ~~method~~use of claim 15, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.

18. The ~~method~~use of claim 15, wherein the antibody or antigen-binding fragment thereof that binds to human PD-1 is a humanized antibody.

19. The ~~method~~use of any one of claims 1 to 18, wherein the inhibitor of human CD73 comprises:

(a) an antibody that binds to human CD73 and comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and

the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and

comprising a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);

the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and

the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);

(b) an antibody that binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;

(c) an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;

(d) an antibody that binds to human CD73 and comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and

the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and

an antibody comprising a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);

the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and

the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);

(e) an antibody that binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;

(f) an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31;
(g) an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31;
(h) an antibody selected from the group consisting of 11E1, Medi9447, CPI-006, and BMS-986179; or
(i) an inhibitor selected from the group consisting of CB-708 and AB680.

20. The ~~method~~use of any one of claims 1 to 19, wherein the inhibitor of human CD73 is an antibody that binds to human CD73 and comprises:

a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and

the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and

a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);

the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and

the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21).

21. The ~~method~~use of any one of claims 1 to 19, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70.

22. The ~~method~~use of any one of claims 1 to 19, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 and competes for binding to

human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25.

23. The ~~method~~use of any one of claims 1 to 19, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 and comprises:

a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and

the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and

a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);

the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and

the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).

24. The ~~method~~use of any one of claims 1 to 19, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70.

25. The ~~method~~use of any one of claims 1 to 19, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

26. The ~~method~~use of any one of claims 1 to 19, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid

sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

27. The ~~method~~use of any one of claims 1 to 19, wherein the inhibitor of human CD73 comprises an antibody selected from the group consisting of 11E1, Medi9447, CPI-006, and BMS-986179.

28. The ~~method~~use of any one of claims 1 to 19, wherein the inhibitor of human CD73 is selected from the group consisting of CB-708 and AB680.

29. The ~~method~~use of claim 20, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:22 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:23~~.~~

~~30. The method of claim 20,~~; or wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:24 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:25.

~~31~~30. The ~~method~~use of claim 23, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:62 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:61.

~~32~~31. The ~~method~~use of claim 23, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:30 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:31~~.~~

~~33. The method of claim 23,~~; or wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:63 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:61~~.~~

~~34. The method of claim 23,~~; or wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:33 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:31.

~~35~~32. The ~~method~~use of any one of claims 1 to ~~34~~31, wherein the cancer is selected from bladder cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, anal cancer, endometrial cancer, kidney cancer, oral cancer, head and neck cancer, liver cancer, melanoma, mesothelioma, non-small cell lung cancer, small cell lung cancer, non-melanoma skin cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, thyroid cancer, renal cell carcinoma, and Merkel cell carcinoma.

~~36. The method of any one of claims 1 to 34, wherein the cancer is selected from melanoma, endometrial cancer, lung cancer, kidney cancer, bladder cancer, breast cancer, pancreatic cancer, colon cancer, head and neck cancer, colorectal cancer, ovarian, liver cancer, or renal cell carcinoma.~~

~~37. The method of any one of claims 1 to 34, wherein the cancer is melanoma.~~

~~38. The method of any one of claims 1 to 34, wherein the cancer is breast cancer.~~

~~39~~33. ~~A method of treating a cancer selected from bladder cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, anal cancer, endometrial cancer, kidney cancer, oral cancer, head and neck cancer, liver cancer, melanoma, mesothelioma, non-small cell lung cancer, small cell lung cancer, non-melanoma skin cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, thyroid cancer, renal cell carcinoma, and Merkel cell carcinoma in a subject, comprising administering to the subject:~~ Use of:

(i) an inhibitor of A2A/A2B;

(ii) an inhibitor of PD-1/PD-L1, which is an antibody or antigen-binding fragment thereof that binds to human PD-1, wherein the antibody or antigen-binding

fragment thereof comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);

the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and

the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);

the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and

the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11); and

(iii) an antibody that binds to human CD73, wherein the antibody that binds to human CD73:

~~(a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:~~

~~the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);~~

~~the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and~~

~~the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and~~

~~comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:~~

~~the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);~~

~~the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and~~

~~the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);~~

~~(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;~~

~~(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;~~

~~(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:~~

~~the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);~~

~~the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and~~

~~the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and~~

~~wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:~~

~~the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);~~

~~the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and~~

~~the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);~~

~~(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;~~

~~(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31; or~~

~~(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31~~

(a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and

the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and

comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);

the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and

the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);

(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;

(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;
(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);
the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and
the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and
wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);
the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and
the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);
(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;
(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31; or
(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31.;
in the manufacture of a medicament for the treatment of a cancer selected from bladder cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, anal cancer, endometrial cancer, kidney cancer, oral cancer, head and neck cancer, liver cancer, melanoma, mesothelioma, non-small cell lung cancer, small cell lung cancer, non-melanoma skin cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, thyroid cancer, renal cell carcinoma, and Merkel cell carcinoma.

~~40~~34. The ~~method~~use of claim ~~39~~33, wherein the antibody that binds to human CD73 comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and

the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and

wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);

the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21).

~~41~~35. The ~~method~~use of claim ~~40~~34, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:22~~.~~

~~42. The method of claim 40,~~; or wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:24~~.~~

~~43. The method of claim 40,~~; or wherein the VL domain comprises the amino acid sequence set forth in SEQ ID NO:23~~.~~

~~44. The method of claim 40,~~; or wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO:25~~.~~

~~45. The method of claim 40,~~; or wherein the VH domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:22 and the VL domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:23~~.~~

~~46. The method of claim 40,~~; or wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:22 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:23~~.~~

~~47. The method of claim 40,~~; or wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:24 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:25.

4836. The methoduse of claim 3933, wherein the antibody that binds to human CD73 binds at an epitope within amino acids 40-53 of SEQ ID NO:70.

49. The method of claim 39,; or wherein the antibody binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25.

50. The method of claim 39,; or wherein the antibody that binds to human CD73 comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and

the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and

wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);

the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and

the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).

5137. The methoduse of claim 5036, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35);

the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36);

the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);

the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and

the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).

~~52~~38. The ~~method~~use of claim ~~51~~37, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO: 62~~.~~

~~53. The method of claim 51,~~; or wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:30; or wherein the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 61.

~~54. The method of claim 51, wherein the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 61.~~

~~55~~39. ~~The method of claim 51~~The use of claim 37, wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 31~~.~~

~~56. The method of claim 51,~~; or wherein the VH domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 62 and the VL domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 61~~.~~

~~57. The method of claim 51,~~; or wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO: 62 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 61~~.~~

~~58. The method of claim 51,~~; or wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 30 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 31.

~~59~~40. The ~~method~~use of claim ~~50~~36, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYEGSNK (SEQ ID NO:40);

the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36);

the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);

the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and

the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).

6041. The methoduse of claim 5940, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO: 63.

61. The method of claim 59,; or wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:33.

62. The method of claim 59,; or wherein the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 61.

63. The method of claim 59,; or wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 31.

64. The method of claim 59,; or wherein the VH domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 63 and the VL domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 61.

~~65. The method of claim 59,~~; or wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO: 63 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 61~~.~~

~~66. The method of claim 59,~~; or wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 33 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 31.

~~67~~42. The ~~method~~use of claim ~~39~~33, wherein the antibody that binds to human CD73 binds at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70~~.~~

~~68. The method of claim 39,~~; or wherein the antibody binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31~~.~~

~~69. The method of claim 39,~~; or wherein the antibody binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

~~70~~43. The ~~method~~use of any one of claims ~~39~~33 to ~~69~~42, wherein the inhibitor of A2A/A2B is selected from the group consisting of:

3-(5-amino-2-(pyridin-2-ylmethyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(5-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(5-amino-2-((5-(pyridin-2-yl)-2H-tetrazol-2-yl)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(5-amino-2-((5-(pyridin-2-yl)-1H-tetrazol-1-yl)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(5-amino-2-((3-methylpyridin-2-yl)methoxy)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(2-((5-(1H-pyrazol-1-yl)-2H-tetrazol-2-yl)methyl)-5-amino-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(2-((5-(1H-pyrazol-1-yl)-1H-tetrazol-1-yl)methyl)-5-amino-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(5-amino-2-(hydroxy(phenyl)methyl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-(5-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-2-fluorobenzonitrile;

5-amino-7-(3-cyano-2-fluorophenyl)-2-((2,6-difluorophenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-c]pyrimidine-8-carbonitrile;

3-(5-amino-2-((2-fluoro-6-(((1-methyl-2-oxopyrrolidin-3-yl)amino)methyl)phenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-2-fluorobenzonitrile;

3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile;

3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile;

3-(8-amino-2-(amino(2,6-difluorophenyl)methyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile;

3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(2,6-dimethylpyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile;

3-(4-amino-2-(pyridin-2-ylmethyl)-7-(pyrimidin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile;

3-(4-amino-2-((3-fluoropyridin-2-yl)methyl)-7-(pyrimidin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile;

3-(4-amino-2-((3-fluoropyridin-2-yl)methyl)-7-(pyridin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile; and

3-(4-amino-7-(1-methyl-1H-pyrazol-5-yl)-2-(pyridin-2-ylmethyl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)-2-fluorobenzonitrile;

or a pharmaceutically acceptable salt of any of the aforementioned.

~~71~~44. The ~~method~~use of any one of claims ~~39~~33 to ~~69~~42, wherein the inhibitor of A2A/A2B is selected from the group consisting of:

7-(5-methylfuran-2-yl)-3-[[6-[[(3S)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine;

3-(5-amino-2-((5-(pyridin-2-yl)-2H-tetrazol-2-yl)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile;

3-[2-amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile; and

6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine;

5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine;

or a pharmaceutically acceptable salt of any of the aforementioned.

~~72~~45. The ~~method~~use of any one of claims ~~39~~33 to ~~69~~42, wherein the inhibitor of A2A/A2B is 3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.

~~73~~46. ~~—~~The ~~method~~use of any one of claims ~~39~~33 to ~~69~~42, wherein the inhibitor of A2A/A2B is 3-(5-amino-2-((5-(pyridin-2-yl)-2H-tetrazol-2-yl)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.

~~74~~47. ~~—~~The ~~method~~use of any one of claims ~~39~~33 to ~~73~~46, wherein the cancer is selected from melanoma, endometrial cancer, lung cancer, kidney cancer, bladder cancer, breast cancer, pancreatic cancer, colon cancer, head and neck cancer, colorectal cancer, ovarian, liver cancer, or renal cell carcinoma.

~~75. The method of any one of claims 39 to 73, wherein the cancer is melanoma.~~

~~76. The method of any one of claims 39 to 73, wherein the cancer is breast cancer.~~

~~77~~48. ~~A method of treating breast cancer in a subject, comprising administering to the subject:~~The use of:

(i) an inhibitor of A2A/A2B, which is 3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;

(ii) an inhibitor of PD-1/PD-L1, which is an antibody or antigen-binding fragment thereof that binds to human PD-1, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);

the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and

the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);

the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and

the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11); and

(iii)~~—~~ an antibody that binds to human CD73, wherein the antibody that binds to human CD73:

(a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and

the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and

comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);
the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and
the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);
(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;
(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;
(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);
the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and
the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and
wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);
the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and
the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);
(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;
(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31; or
(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31~~(a)~~ ;
in the manufacture of a medicament for the treatment of breast cancer.

~~78. A method of treating breast cancer in a subject, comprising administering to the subject:~~

(i) an inhibitor of A2A/A2B, which is 3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;

(ii) an inhibitor of PD-1/PD-L1, which is (*R*)-1-((7-cyano-2-(3'-(3-(((*R*)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof; and

(iii) an antibody that binds to human CD73, wherein the antibody that binds to human CD73:

(a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and

the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and

comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);

the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and

the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);

(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;

(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;

(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and

~~the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and~~

~~wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:~~

~~the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);~~

~~the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and~~

~~the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);~~

~~(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;~~

~~(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31;~~ ~~or~~

~~(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31.~~

~~79. The method of claim 77 or 78, wherein the breast cancer is breast adenocarcinoma tumor.~~

~~80. The method of any one of claims 1 to 79, wherein the cancer has a high adenosine signature.~~

~~81. The method of any one of claims 1 to 80, wherein the inhibitor of A2A/A2B is administered to the subject in a dosage of from about 0.1 mg to about 1000 mg on a free base basis.~~

~~82. The method of any one of claims 1 to 81, wherein the A2A/A2B inhibitor is administered to the subject once-daily, every other day, or once-weekly.~~

~~83. The method of any one of claims 1 to 82, wherein the inhibitor of A2A/A2B, inhibitor of PD-1/PD-L1, and inhibitor of human CD73 are administered simultaneously.~~

84. The method of any one of claims 1 to 82, wherein the inhibitor of A2A/A2B, inhibitor of PD-1/PD-L1, and inhibitor of human CD73 are administered sequentially.

85. A method of treating cancer in a subject, comprising administering to the subject:

(i) an inhibitor of PD-1/PD-L1; and

(ii) an inhibitor of human CD73.

86. A method of treating a cancer selected from neck and head cancer, lung cancer, ovarian cancer, prostate cancer, breast cancer, bladder cancer, colorectal cancer, gastric cancer, gastroesophageal junction cancer, anal cancer, liver cancer, or pancreatic cancer in a subject, comprising administering to the subject:

(i) an inhibitor of PD-1/PD-L1, which is an antibody or antigen-binding fragment thereof that binds to human PD-1, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);

the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and

the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);

the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and

the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11); and

(ii) an antibody that binds to human CD73, wherein the antibody that binds to human CD73:

~~(a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:~~

~~the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);~~

~~the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and~~

~~the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and~~

~~comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:~~

~~the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);~~

~~the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and~~

~~the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);~~

~~(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;~~

~~(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;~~

~~(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:~~

~~the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);~~

~~the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and~~

~~the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and~~

~~wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:~~

~~the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);~~

~~the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and~~

~~the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);~~

~~(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;~~

~~(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31;~~ ~~or~~

(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

87. A method of treating a cancer selected from squamous cell carcinoma of the neck and head (SCCNH), non-small cell lung cancer (NSCLC), ovarian cancer, castration-resistant prostate cancer (CRPC), triple-negative breast cancer (TNBC), bladder cancer, metastatic colorectal cancer (mCRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction (GEJ) cancer, hepatocellular carcinoma (HCC), and squamous carcinoma of the anal canal (SCAC) in a subject, comprising administering to the subject:

(i) an inhibitor of PD-1/PD-L1, which is an antibody or antigen-binding fragment thereof that binds to human PD-1, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);

the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and

the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);

the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and

the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11); and

(ii) an antibody that binds to human CD73, wherein the antibody that binds to human CD73:

~~(a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:~~

~~the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);~~
~~the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and~~
~~the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and~~
~~comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:~~
~~the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);~~
~~the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and~~
~~the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);~~
~~(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;~~
~~(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;~~
~~(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:~~
~~the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);~~
~~the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and~~
~~the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and~~
~~wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:~~
~~the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);~~
~~the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and~~
~~the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);~~
~~(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;~~

~~(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31;~~ ~~or~~

~~(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31.~~

~~88. A method of treating a cancer selected from neck and head cancer, lung cancer, ovarian cancer, prostate cancer, breast cancer, bladder cancer, colorectal cancer, gastric cancer, gastroesophageal junction cancer, anal cancer, liver cancer, and pancreatic cancer in a subject, comprising administering to the subject:~~

~~an inhibitor of PD-1/PD-L1, which is retifanlimab; and~~

~~an antibody that binds to human CD73, which is ANTIBODY Y.~~

~~89. A method of treating a cancer selected from squamous cell carcinoma of the neck and head (SCCNH), non-small cell lung cancer (NSCLC), ovarian cancer, castration-resistant prostate cancer (CRPC), triple-negative breast cancer (TNBC), bladder cancer, metastatic colorectal cancer (mCRC), and pancreatic cancer in a subject, comprising administering to the subject:~~

~~(i) an inhibitor of PD-1/PD-L1, which is retifanlimab; and~~

~~(ii) an antibody that binds to human CD73, which is ANTIBODY Y.~~

49. Use of:

(i) an inhibitor of A2A/A2B, which is 3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;

(ii) an inhibitor of PD-1/PD-L1, which is (*R*)-1-((7-cyano-2-(3'-(3-(((*R*)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof; and

(iii) an antibody that binds to human CD73, wherein the antibody that binds to human CD73:

(a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);
the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and
the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and
comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);
the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and
the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);
(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;
(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;
(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);
the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and
the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and
wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);
the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and
the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);
(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;
(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31; or

(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31;
in the manufacture of a medicament for the treatment of breast cancer.

50. The use of claim 48 or 49, wherein the breast cancer is breast adenocarcinoma tumor.

51. The use of any one of claims 1 to 50, wherein the cancer has a high adenosine signature.

52. The use of any one of claims 1 to 51, wherein the medicament comprising the inhibitor of A2A/A2B is to be administered to the subject in a dosage of from about 0.1 mg to about 1000 mg on a free base basis.

53. The use of any one of claims 1 to 52, wherein the medicament comprising the A2A/A2B inhibitor is to be administered to the subject once-daily, every other day, or once-weekly.

54. Use of:

(i) an inhibitor of PD-1/PD-L1, which is an antibody or antigen-binding fragment thereof that binds to human PD-1, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);

the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and

the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);

the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and

the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11); and

(ii) an antibody that binds to human CD73, wherein the antibody that binds to human CD73:

(a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and

the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and

comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);

the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and

the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);

(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;

(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;

(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and

the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and

wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);

the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and

the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);

(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;

(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31; or

(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31;

in the manufacture of a medicament for the treatment of a cancer selected from neck and head cancer, lung cancer, ovarian cancer, prostate cancer, breast cancer, bladder cancer, colorectal cancer, gastric cancer, gastroesophageal junction cancer, anal cancer, liver cancer, or pancreatic cancer.

55. Use of:

(i) an inhibitor of PD-1/PD-L1, which is an antibody or antigen-binding fragment thereof that binds to human PD-1, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);

the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and

the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);

the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and

the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11); and

(ii) an antibody that binds to human CD73, wherein the antibody that binds to human CD73:

(a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:16);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:17); and

the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:18); and

comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:19);

the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:20); and

the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:21);

(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;

(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25;

(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and

the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and

wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);
the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and
the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);
(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;
(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31; or
(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31'
in the manufacture of a medicament for the treatment of a cancer selected from squamous cell carcinoma of the neck and head (SCCNH), non-small cell lung cancer (NSCLC), ovarian cancer, castration-resistant prostate cancer (CRPC), triple-negative breast cancer (TNBC), bladder cancer, metastatic colorectal cancer (mCRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction (GEJ) cancer, hepatocellular carcinoma (HCC), and squamous carcinoma of the anal canal (SCAC).

56. Use of:

(i) an inhibitor of PD-1/PD-L1, which is retifanlimab; and

(ii) an antibody that binds to human CD73, which is ANTIBODY Y;

in the manufacture of a medicament for the treatment of cancer selected from neck and head cancer, lung cancer, ovarian cancer, prostate cancer, breast cancer, bladder cancer, colorectal cancer, gastric cancer, gastroesophageal junction cancer, anal cancer, liver cancer, and pancreatic cancer.

57. Use of:

(i) an inhibitor of PD-1/PD-L1, which is retifanlimab; and

(ii) an antibody that binds to human CD73, which is ANTIBODY Y;

in the manufacture of a medicament for the treatment of a cancer selected from squamous cell carcinoma of the neck and head (SCCNH), non-small cell lung cancer (NSCLC), ovarian cancer, castration-resistant prostate cancer (CRPC), triple-negative breast cancer (TNBC), bladder cancer, metastatic colorectal cancer (mCRC), and pancreatic cancer.